Subject(s)
Epstein-Barr Virus Infections/diagnosis , Esophageal Diseases/diagnosis , Herpesvirus 4, Human/isolation & purification , Lymphoproliferative Disorders/diagnosis , Skin Ulcer/diagnosis , Aged, 80 and over , Cell Proliferation , Epstein-Barr Virus Infections/pathology , Esophageal Diseases/pathology , Female , Humans , Lymphoproliferative Disorders/pathology , Skin Ulcer/pathologyABSTRACT
Histone deacetylase 9 (HDAC9) is expressed in B cells, and its overexpression has been observed in B-lymphoproliferative disorders, including B-cell non-Hodgkin lymphoma (B-NHL). We examined HDAC9 protein expression and copy number alterations in primary B-NHL samples, identifying high HDAC9 expression among various lymphoma entities and HDAC9 copy number gains in 50% of diffuse large B-cell lymphoma (DLBCL). To study the role of HDAC9 in lymphomagenesis, we generated a genetically engineered mouse (GEM) model that constitutively expressed an HDAC9 transgene throughout B-cell development under the control of the immunoglobulin heavy chain (IgH) enhancer (Eµ). Here, we report that the Eµ-HDAC9 GEM model develops splenic marginal zone lymphoma and lymphoproliferative disease (LPD) with progression towards aggressive DLBCL, with gene expression profiling supporting a germinal center cell origin, as is also seen in human B-NHL tumors. Analysis of Eµ-HDAC9 tumors suggested that HDAC9 might contribute to lymphomagenesis by altering pathways involved in growth and survival, as well as modulating BCL6 activity and p53 tumor suppressor function. Epigenetic modifications play an important role in the germinal center response, and deregulation of the B-cell epigenome as a consequence of mutations and other genomic aberrations are being increasingly recognized as important steps in the pathogenesis of a variety of B-cell lymphomas. A thorough mechanistic understanding of these alterations will inform the use of targeted therapies for these malignancies. These findings strongly suggest a role for HDAC9 in B-NHL and establish a novel GEM model for the study of lymphomagenesis and, potentially, preclinical testing of therapeutic approaches based on histone deacetylase inhibitors.
Subject(s)
B-Lymphocytes/enzymology , Gene Expression Regulation, Neoplastic , Histone Deacetylases/genetics , Lymphoma, B-Cell/enzymology , Lymphoma, B-Cell/genetics , Lymphoproliferative Disorders/enzymology , Lymphoproliferative Disorders/genetics , Repressor Proteins/genetics , Acetylation , Animals , B-Lymphocytes/pathology , Cell Cycle/genetics , Gene Expression Profiling , Gene Rearrangement, B-Lymphocyte, Heavy Chain/genetics , HeLa Cells , Histone Deacetylases/metabolism , Humans , Lymphoma, B-Cell/pathology , Lymphoproliferative Disorders/pathology , Mice, Transgenic , Proto-Oncogene Proteins c-bcl-6/metabolism , Repressor Proteins/metabolism , Tumor Suppressor Protein p53/metabolismABSTRACT
GLI1 oncogene has been implicated in the pathobiology of several neoplasms including diffuse large B-cell lymphoma (DLBCL). However, mechanisms underlying GLI1-increased activity in DLBCL are poorly characterized. Herein, we demonstrate that IKKß phosphorylates GLI1 in DLBCL. IKKß activation increased GLI1 protein levels and transcriptional activity, whereas IKKß silencing decreased GLI1 levels and transcriptional activity. Tumor necrosis factor-α (TNFα) mediated IKKß activation-impaired GLI1 binding with the E3 ubiquitin ligase-ITCH, leading to decreased K48-linked ubiquitination/degradation of GLI1. We found 8 IKKß-dependent phosphorylation sites that mediate GLI1 stability. Mutating or deleting these residues facilitated GLI1-ITCH interaction and decreased the protective effect of TNFα on GLI1 stability. IKKß-GLI1 crosstalk is significant because combined inhibition of both molecules resulted in synergistic suppression of DLBCL viability in vivo and in vitro. By linking IKKß-mediated nuclear factor-κB activity with GLI1, we identified a crosstalk between these 2 pathways that can inform the design of novel therapeutic strategies in DLBCL.
